Catherine Tomaro-Duchesneau
Canada
Research Article
Effect of Orally Administered Microencapsulated FA-Producing L. fermentum on Markers of Metabolic Syndrome: An In Vivo Analysis
Author(s): Jasmine Bhathena, Catherine Tomaro-Duchesneau, Christopher Martoni, Meenakshi Malhotra, Arun Kulamarva, Aleksandra Malgorzata Urbanska, Arghya Paul and Satya PrakashJasmine Bhathena, Catherine Tomaro-Duchesneau, Christopher Martoni, Meenakshi Malhotra, Arun Kulamarva, Aleksandra Malgorzata Urbanska, Arghya Paul and Satya Prakash
Ferulic Acid (FA) is a natural phenolic acid produced by a number of lactic acid bacteria. FA has a number of beneficial properties, including: antioxidant activity, anti-tumorigenic properties and cholesterol-lowering capabilities. Our group has previously screened lactobacilli for FA production, and selected L. fermentum ATCC 11976 (L.f. 11976) as one of the best producers. Alginate-polylysine-alginate (APA) microencapsulation has proven successful for the oral delivery of this strain to the colon, where production of FA is greatest. The aim of this study was to investigate the role of APA microencapsulated L.f. 11976 to modulate markers of metabolic syndrome. The antioxidant activity, as a potential mechanism of action to treat/prevent metabolic syndrome of free and microencapsulated L.f.
11976 was quantified. A high-fat fed BioF1B Golden Syrian hamster model was used to inv.. View More»
